Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.
Nakamura R, Fujii H, Yamada T, Matsui Y, Yaoi T, Honda M, Tanaka N, Miyagawa-Hayashino A, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Konishi E, Itoh K, Takayama K.
Nakamura R, et al. Among authors: konishi e.
JTO Clin Res Rep. 2023 May 12;4(6):100525. doi: 10.1016/j.jtocrr.2023.100525. eCollection 2023 Jun.
JTO Clin Res Rep. 2023.
PMID: 37426308
Free PMC article.